Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has a positive serum or CSF ELISA MAC-IgM test indicating active/recent WNV infection, or the Subject resides in or has traveled to geographic areas with at least one of the following characteristics within the last seven days:~  1. Documented evidence of WNV infected mosquitoes or sentinel animals within the last 30 days~ 2. Documented evidence of WNV infected dead animals within the last 30 days~ 3. Documented human cases of WNV infection/disease within the last two weeks~* Subject is between \>18 and \<75 years of age.~* Subject has developed a febrile disease with new neurological findings \<4 days prior to the current hospitalization.~* Subject has had an oral temperature of \>38 degrees Celsius within 48 hours of study entry.~* Subject must have one or more of the following acute signs at the time of study entry:~  1. Signs of meningitis (nuchal rigidity)~ 2. Signs of encephalitis (changes in mental status)~ 3. Evidence of brainstem, cranial nerve, or cerebellar dysfunction~ 4. Limb weakness.~* Subject must have a CSF examination within 48 hours of study entry showing:~  1. Absence of any organisms on Gram or fungal stains~ 2. White blood cell count of \> 4 per mm3 (corrected for significant red blood cell contamination)~ 3. Ratio of CSF glucose: plasma glucose of \>0.40; and CSF protein \>30 mg/dL~* Subjects with reproductive potential must agree to practice adequate birth control methods to protect themselves and their partners from conception as defined below:~  1. Men with reproductive potential are eligible to participate if they use an acceptable method of contraception (such as a condom with spermicide).~ 2. Women with childbearing potential are eligible to participate if they are surgically sterile (via hysterectomy or bilateral tubal ligation) at least one year post-menopausal, or are using an acceptable method of contraception (such as oral, topical, or injected contraception, IUD, Nuva-Ring®, or double barrier method such as diaphragm and condom with spermicide).~Exclusion Criteria:~* Subject (or family or legal guardian) requests Do Not Resuscitate or Do Not Intubate orders.~* Subject has multi-system organ failure at the time of screening or is not expected to survive the next 12 months due to another cause.~* Subject has a history of any vaccine administration \<30 days prior to study entry.~* Subject has a possible history of traumatic neuritis \<7 days prior to study entry (e.g., acupuncture, any needle-administered drugs, automobile accident, and/or blunt trauma).~* Subject is female and is pregnant or breastfeeding. (If the Subject is not postmenopausal or has not been surgically sterilized, a negative serum pregnancy test is required within 72 hours prior to the administration of the first dose of study drug.)~* Subject has any of the following clinically significant abnormal laboratory results:~  1. Serum creatinine greater than 3.0 mg/dL or study Subject requires hemodialysis~ 2. Liver function tests twice the upper limit of normal~ 3. Total bilirubin level twice the upper limit of normal~ 4. PT or INR twice the upper limit of normal~* Documented presence of bacterial or non-WNV viral agents in CSF~* Principal Investigator is of the opinion that the Subject's medical condition(s) or state of mental health would prevent adherence to protocol requirements or hinder interpretation of clinical study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).